GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Medicus Sciences Acquisition Corp (NAS:MSAC) » Definitions » Debt-to-EBITDA

MSAC (Medicus Sciences Acquisition) Debt-to-EBITDA : 0.00 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Medicus Sciences Acquisition Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medicus Sciences Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. Medicus Sciences Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. Medicus Sciences Acquisition's annualized EBITDA for the quarter that ended in Sep. 2022 was $-0.70 Mil. Medicus Sciences Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medicus Sciences Acquisition's Debt-to-EBITDA or its related term are showing as below:

MSAC's Debt-to-EBITDA is not ranked *
in the Diversified Financial Services industry.
Industry Median: 3.92
* Ranked among companies with meaningful Debt-to-EBITDA only.

Medicus Sciences Acquisition Debt-to-EBITDA Historical Data

The historical data trend for Medicus Sciences Acquisition's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Sciences Acquisition Debt-to-EBITDA Chart

Medicus Sciences Acquisition Annual Data
Trend Dec20 Dec21
Debt-to-EBITDA
N/A -

Medicus Sciences Acquisition Quarterly Data
Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-EBITDA Get a 7-Day Free Trial - - - - -

Competitive Comparison of Medicus Sciences Acquisition's Debt-to-EBITDA

For the Shell Companies subindustry, Medicus Sciences Acquisition's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicus Sciences Acquisition's Debt-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Medicus Sciences Acquisition's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medicus Sciences Acquisition's Debt-to-EBITDA falls into.



Medicus Sciences Acquisition Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medicus Sciences Acquisition's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.615
=0.00

Medicus Sciences Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.696
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.


Medicus Sciences Acquisition  (NAS:MSAC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medicus Sciences Acquisition Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medicus Sciences Acquisition's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicus Sciences Acquisition Business Description

Traded in Other Exchanges
N/A
Address
152 West 57th Street, Floor 20, New York, NY, USA, 10019
Medicus Sciences Acquisition Corp is a blank check company.
Executives
Eric Cheng officer: Chief Business Officer 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Kenneth Berkovitz director 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Christopher Kaster director 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Ross Levine director 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Judah Drillick officer: Chief Financial Officer 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Jacob Gottlieb director, 10 percent owner, officer: Executive Chairman 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Medicus Sciences Holdings Llc 10 percent owner 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Michael Castor director, 10 percent owner, officer: Chief Executive Officer 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019